since his departure from lsu health sciences center simpkins has focused on the development of his biotechnology company, vivacelle bio founded in 2013. the company web page is vivacellebio.com. vivacelle bio, inc. was organized for the purpose of commercializing a new resuscitation fluid, developed by dr. simpkins, that is based on phospholipid nanoparticles. his experiments showed that this resuscitation fluid, named vbi-1, could be used safely to replace most of the circulating blood volume. his experiments, in collaboration with physicist juan rodriguez, also showed that this resuscitation fluid readily absorbed nitric oxide. moreover, in animal experiments vbi-1 was superior to the standard, ringer's lactate in reversing hypovolemia after blood loss and restoring the blood pressure. on november 22, 2011 simpkins was granted his first patent, us patent #8063020. this fluid is designed to promote survival after hypovolemic shock for any reason such as blood loss, massive infection, neurological injury, acute radiation injury, burns or childhood diarrhea. at this point the blood substitutes, blood products, hetastarch based colloids, albumin and hypertonic solutions have all been shown to have significant complications. in contrast, all of the components of vbi-1 are naturally occurring and/or metabolizable. to date tests have shown the safety profile of vbi-1 to be superior to all other fluid therapy including blood and ringer's lactate. since 2011 multiple us and international patents for vbi-1 and its derivatives have been granted to dr. simpkins. as of june 2019 nine us patents and thirty-three patents in international jurisdictions have been issued to him as the inventor. the us patents and pending applications are listed at, https://patents.justia.com/inventor/cuthbert-o-simpkins. vivacelle bio has recently received clearance from the fda to enroll patients into clinical trials of two products in its pipeline. one is vbi-1 which is designed to treat shock caused by blood loss and vbi-s which is designed to treat shock caused by sepsis.